Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) shot up 6.6% on Friday . The stock traded as high as $3.39 and last traded at $3.39. 2,287,100 shares changed hands during mid-day trading, an increase of 207% from the average session volume of 743,981 shares. The stock had previously closed at $3.18.
Several research firms have weighed in on CPRX. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, March 15th. ValuEngine raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, May 14th. Finally, BidaskClub raised Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.25.
The stock has a market cap of $348.83 million, a PE ratio of -16.14 and a beta of 1.57.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). equities analysts expect that Catalyst Pharmaceuticals Inc will post -0.34 earnings per share for the current fiscal year.
In other Catalyst Pharmaceuticals news, Director Donald A. Denkhaus acquired 20,000 shares of the stock in a transaction on Wednesday, May 30th. The stock was purchased at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the purchase, the director now directly owns 120,000 shares in the company, valued at $450,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have acquired 49,000 shares of company stock valued at $152,740. 9.60% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in CPRX. Two Sigma Securities LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 132.2% in the 4th quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 15,178 shares during the last quarter. Caxton Corp acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $129,000. Lido Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth about $142,000. MetLife Investment Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $144,000. Finally, Hoylecohen LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $172,000. 53.33% of the stock is currently owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.